So in urothelial carcinoma we have at the moment, I mean we’ve done a huge effort trying to find biomarkers in urothelial carcinoma. Right now we have four important biomarkers. We have FGFR for the first time, erdafitinib. This is probably the most robust data that we have from the THOR trial. We have erdafitinib approved by both the FDA and the EMA. And we know that FGFR3 is a mutation that correlates with treatment response...
So in urothelial carcinoma we have at the moment, I mean we’ve done a huge effort trying to find biomarkers in urothelial carcinoma. Right now we have four important biomarkers. We have FGFR for the first time, erdafitinib. This is probably the most robust data that we have from the THOR trial. We have erdafitinib approved by both the FDA and the EMA. And we know that FGFR3 is a mutation that correlates with treatment response. So we know that for sure. We have heard too. There are some data presented at this meeting about the DV combination in the first line, which is really exciting. I want to hear the data. And we also have HER2 for Trastuzumab deruxtecan. So HER2 is also, we have some robust data. We have ctDNA. And for ctDNA we have the results from the Invictus and Ignite 11, which is going to be presented on Monday, I think. It’s also very promising. And finally, these three are the most important ones.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
